anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The trough value of anti-Xa level of this group should be remain 0.1～0.2IU/mL. This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
Several randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, six randomized controlled trials demonstrated the efficacy and safety of endovascular thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score \[ASPECTS\] ≥3 or infarct core \<100ml). Patients with extra-large infarct core (volume greater than 100 mL, ASPECTS score of 0 to 2) accounted for a small proportion of these trials. Therefore, the role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. That is to say, exactly where the lower limit of endovascular thrombectomy is unknown. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.
The utility model relates to a multiple smearing recovery patch, the structure of which includes a transparent film and a lining subbase, wherein a sticky layer is arranged under the transparent film. A drug-storehouse layer is arranged with under the sticky layer. Another sticky layer is arranged under the drug- storehouse layer. The most bottom layer is the lining subbase. The drug-storehouse layer can be divided into a general medical glue ratio layer, a medicament layer with high volatility, and a medicament layer with strong pungency. The thickness of the drug-storehouse layer is between 1mm-2mm. The effect of the utility model is that the multiple smearing recovery patch maintains the advantages of the white plaster, and increases the drug content. Due to the drug-storehouse layer, the effective time of the drug is increased, and the drug effect is enhanced, thereby providing curing and health care patch.
Pulmonary Hypertension (PH) is a multifaceted disease and is associated with significant morbidity and mortality if untreated1. Diagnosing PH can be challenging and often delayed2. Multiple international registries included REVEAL3 and COMPERA4 have all demonstrated that diagnostic delay and suboptimal treatment prescription led poor 1 year-survival in patient with PH. In recent years, significant progress has been made in diagnosing, risk stratification, and treatment for patients with PH1. A dedicated PH service has been established in ambulatory clinic to streamline the management of these complex patients. This registry therefore aims to investigate the progression disease and its impact on the quality of life (QoL) of the patients who are managed at the dedicated PH clinic.
A system for medicine dosage compliance may comprise a dispensing component that provides for medicine to be dispensed based at least upon authorized identification of a user and a secondary authorizer. The dispensing component may comprise an identity authentication component that automatically authenticates an identity of the user and the secondary authorizer at the time of a dispensing event. The system may further comprise a communication component providing one or more notifications to one or more third parties. The communication component may comprise a wireless personal area networking component that sets up a local networking connection between the dispensing component and a local device to share data between the dispensing component and a local device. The local device may communicatively be coupled to a remote network component. A notification component may generate notification information of the dispensing event for one or more third parties.
PURPOSE:To obtain the titled pharmaceutical, containing a phospholipid having saturated acyl groups and glycolipid having sialic acid groups as membrane constituent components, capable of a stably circulating through the body together with blood for a long period after intravenous administration and capable of increasing target effects of a drug on specific lesions. CONSTITUTION:A liposome pharmaceutical obtained by dissolving (A) a phospholipid having saturated acyl groups and (B) a glycolipid having sialic acid groups in an organic solvent, such as diethyl ether, adding a solution containing a drug (e.g. anticancer agent, antibiotic substance, antiprotozoal agent, enzymic agent, anticoagulant or antiallergic agent), emulsifying the resultant blend to provide a W/O type emulsion, evaporating and removing the organic solvent at <=40 deg.C under reduced pressure. Glycerophospholipids having saturated acyl groups or sphingophospholipids (e.g. phosphatidyl choline) are cited as the ingredient (A) and gangliodsides, etc., are cited as the ingredient (B). Especially, the titled pharmaceutical containing the anticancer agent sealed therein is capable of improving remedial effects by administration thereof in thermotherapy.
While transplantation has become the definitive treatment for many people suffering end-stage organ failure, demand exceeds supply. For many years, donation after neurological death represented the principal source of organs for transplantation. In the last decade, prevention measures, improvements in neurocritical care, and decompressive craniectomy have led to a significant decrease in the number of non-directed donors (NDDs). In such situations, alternative sources for organ donation must be identified. Cardiac-arrest patients could provide a solution to this organ shortage. Patients who have experienced unexpected in or out of hospital cardiopulmonary arrest could become organ donors. Organ donation following uncontrolled cardiocirculatory death is currently practiced in many European countries. However, in Canada, it's not yet authorized. Yet, each deceased could save up to four lives. The purpose of this study is to determine the organ potential for a cohort of patient who had died from a cardiopulmonary arrest at the CHUS in 2015 and assess the effect of the implementation of a uDCD program on the number of additional donors.
We report a very rare case of Listeria multiple brain abscesses manifested as delirium, which represented diagnostic and therapeutic challenges overcome only by the close cooperation between Infectious Diseases and Neuroradiology, without which a satisfactory outcome would not be achieved.An elderly man presented with confusion and drowsiness with a background of type-II diabetes mellitus. Although computed tomography of the brain only showed frontal lobe oedema, contrast magnetic resonance (MR) imaging showed numerous irregular rim-enhancing lesions containing central diffusion restriction, suggesting multiple pyogenic cerebral abscesses of unclear aetiology. Thereafter, Listeria monocytogenes was isolated from blood cultures, suggesting this as the causative organism. Deemed unsuitable for neurosurgical drainage, the patient received medical management with a protracted course of antibiotics. This case was extremely challenging, due to 1) the impossibility of source control, 2) the small number of effective antibiotics available to treat this condition, and 3) the inevitable antibiotic side-effects, derived from long-term exposure. A successful outcome was only possible thanks to strict close multidisciplinary follow up, requiring frequent MR imaging and a judicious antibiotic choice, including monitoring of their side-effects. Due to the rarity of this condition, there is lack of guidance on its management, hence the importance of multidisciplinary involvement with very close imaging and antibiotic monitoring.
Two 30 minute infusions of oxytocin, 10 International Units (IU) separated by 30 minutes. To avoid potential unmasking by facial flushing which can occur at the beginning of high rates of oxytocin administration, the first infusion will consist of two steps beginning with a rate of 0.125 IU oxytocin per minute for 5 minutes, then increased to 0.375 IU oxytocin for 25 minutes. The second infusion will be a constant rate of 0.333 IU oxytocin per minute for 30 minutes.
The UMPIRE trial has been modelled on similar trials running concurrently in Australia and New Zealand. The design is straight forward in making comparisons between cardiovascular preventative therapy delivered as a polypill (the Red Heart Pill) on the one hand, and as separate component multiple tablets (usual care) on the other hand. In both groups (the polypill group and the usual care group,) the GP or managing physician will be able to adjust or add additional medications as appropriate to meet the targets for control of blood pressure, cholesterol and other risk factors as directed by local or national guidelines. The Primary endpoint - adherence to prescribed cardiovascular preventative medication at the end of the trial follow-up - will be evaluated by self reported use of anti-platelet, statin and blood pressure lowering therapy. This evaluation will be supported by the recording of blood pressure and cholesterol levels, and measuring the differences between the two groups at the end of the trial. Treatment allocation is open label - both investigator and subject will know which arm of the study they are on. Patients will be identified and recruited from GP surgeries or hospital clinics, and also via local advertisement. Recruitment into the study is planned to start in Summer 2010 with a 12 month recruitment phase. Recruited subjects will spend between 12 - 30 months (average 18 months) being followed up. The target study population is 1000 patients in European at sites in London, Dublin and Utrecht; and 1000 subjects in India at approximately 30 sites. Subjects will be randomly allocated to receive either the "polypill" or "usual care". If allocated to the polypill group, the study investigator will decide on the version of polypill to be prescribed, and adjust any current medications as necessary. If the subject is in the "usual care" group, they will be seen as needed by their usual doctor between study visits, and continue on their current medicines. Participants will have at least 5 study visits, but no more than 8 study visits, and these visits include registration, randomisation and follow-up visits at 1 month, 6 months, and 12 months, and depending on when the subject is recruited to the study, study visits at 18 and 24 months/end of trial visit. A substudy, PESCA (Protocol ID CR01656, NCT01326676), will be performed in the European participants to assess whether the polypill reduces progression of atherosclerosis. This will be assessed by measuring carotid intima-medial thickness and central systolic blood pressure using the PulseCor device. A second substudy, INPUT, is a process evaluation involving qualitative interviews of a sample of health practitioners and trial participants at the end of the trial (summer 2012) in London and India.
PURPOSE:To provide a medicinal agent having large intestine cancer-preventive effect along with having blood cholesterol-reducing activity, containing, as active ingredient, a partial hydrolyzate of glucomannan with a specific molecular weight range derived from devil's tongue. CONSTITUTION:Using, as starting material (s), devil's tongue powder, the glucomannan separated therefrom, or devil's tongue powder decolored and deodorized with an alcohol, the material (s) are partially hydrolyzed through acid hydrolysis or enzymolysis to produce a partial hydrolyzate 2000-5000 in average molecular weight. The objective medicinal agent contains this partial hydrolyzate as active ingredient. The above partial hydrolysis is pref. enzymolysis in terms of regulating the degree of decomposition, and it is desirable to use an endo-type enzyme capable of hydrolyzing the intramolecular beta-glucoside linkage of the glucomannan, esp. a cellulase derived from microorganisms belonging to Aspergillus.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to cardio-vascular surgery and anesthesiology in pediatrics and can be used in operative interventions caused by correction of congenital heart diseases in children. For this purpose 30 minutes before operation beginning 0.375% solution of ropivacaine is introduced into epidural cavity in amount 1 mg/kg. During operation infusion of 0.2% ropivocaine solution is carried out at rate 0.2-0.3 ml/kg/hour. In post-operational period constant infusion of 0.2% ropivocaine solution is continued at rate 0.1-0.2 ml/kg/hour during 2 days. ^ EFFECT: method allows to prevent expressed increase of pulmonary-arterial pressure in response to any stimuli due to post-ganglionic sympathetic blockade preventing activation of simpathico-adrenal system on tone of lesser circulation vessels. ^ 1 ex
There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
β-Adrenoceptors (β-ARs) provide an important therapeutic target for the treatment of cardiovascular disease. Three β-ARs, β1-AR, β2-AR, β3-AR are localized to the human heart. Activation of β1-AR and β2-ARs increases heart rate, force of contraction (inotropy) and consequently cardiac output to meet physiological demand. However, in disease, chronic over-activation of β1-AR is responsible for the progression of disease (e.g. heart failure) mediated by pathological hypertrophy, adverse remodelling and premature cell death. Furthermore, activation of β1-AR is critical in the pathogenesis of cardiac arrhythmias while activation of β2-AR directly influences blood pressure haemostasis. There is an increasing awareness of the contribution of β2-AR in cardiovascular disease, particularly arrhythmia generation. All β-blockers used therapeutically to treat cardiovascular disease block β1-AR with variable blockade of β2-AR depending on relative affinity for β1-AR vs β2-AR. Since the introduction of β-blockers into clinical practice in 1965, β-blockers with different properties have been trialled, used and evaluated, leading to better understanding of their therapeutic effects and tolerability in various cardiovascular conditions. β-Blockers with the property of intrinsic sympathomimetic activity (ISA), i.e. β-blockers that also activate the receptor, were used in the past for post-treatment of myocardial infarction and had limited use in heart failure. The β-blocker carvedilol continues to intrigue due to numerous properties that differentiate it from other β-blockers and is used successfully in the treatment of heart failure. The discovery of β3-AR in human heart created interest in the role of β3-AR in heart failure but has not resulted in therapeutics at this stage.
We present a case of deep surgical site infection (SSI) at a spinal cord stimulator (SCS) trial implantation site, resulting from an allergic reaction to an unknown agent. A 38-year-old female with complex regional pain syndrome began an SCS trial, noting 100% pain relief for 5 days. Fluid drainage from the surgical site was reported on POD6 and trial leads were removed the following day. The patient was hospitalized with sepsis. Blood cultures revealed Staphylococcus aureus. MRIs showed skin breakdown and cellulitis of the paraspinal musculature extending into the epidural space. The patient was maintained with antibiotics and rigorous wound care for 9 days and the surgical site infection resolved. The patient proceeded to SCS implantation, and reported good pain relief with the implanted device.
FIELD: organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of barbituric acid and pharmaceutical composition with inhibitory effect on activity of metalloproteases. New derivatives of barbituric acid corresponds to the general formula (I)   where X, Y, Z are oxygen; R 1  means the group W-V where W is a valent bond or means direct or branched C 1 -C 4 -alkyl group; V is a monocycle taken among the optionally substituted phenyl, pyridyl, piperidyl, thiophenyl, imidazolyl or a bicycle taken among naphthyl, quinolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, benzimidazolyl or indolyl being each of that can be substituted or W-V means optionally substituted C 1 -C 20 -alkyl group; R 2 ,R 3  both are hydrogen atom; R 4 ,R 5  mean independently each of other A-D where A and D have different values indicated in the claim of invention, or R 4 ,R 5  in common with nitrogen atom with which they are bound form a ring that can be broken additionally by N atom and can be substituted as indicated in the claim of invention. Pharmaceutical composition includes at least one compound of the formula (I) and usual substance-carriers and accessory substances additionally. EFFECT: new compound indicated above, valuable biochemical properties. 8 cl, 2 tbl
The invention relates to a nutritional branched polypeptide with efficient broad-spectrum antibacterial and antifungal functions. The nutritional branched structure polypeptide is a polymer polypeptide containing L-lysine and D-lysine structural units, and the molecular weight of the polypeptide is 3000-7000Da, and the polydispersity index of the polypeptide is less than 1.2. The polypeptide with the branched structure has high-efficiency broad-spectrum antibacterial effect on bacteria, fungi and mycoplasma under low concentration, and does not generate drug resistance. Compared with common antibacterial agents, the polypeptide disclosed by the invention has excellent biocompatibility and no cytotoxicity, has no side effect on animals through intravenous injection, and can meet the requirement of in vivo intravenous injection antibacterial. The degradation product is lysine which is a nutrient substance necessary for organisms, and has no toxic or side effect. The polypeptide with the branched structure is synthesized chemically in the whole process without a biological fermentation process, has stable physical, chemical and biological properties, can be combined with other materials in a physical or chemical mode, is synthesized or processed into materials with various forms, and keeps high-efficiency antibacterial performance.
An acid tolerant microorganism Lactobacillus sakei Probio-65 is provided, which microorganism inhibits growth of pathogenic microorganisms, enhances immunity and has anti-allergic effect, so that the microorganism is useful for prevention and treatment of atopic dermatitis, allergy-related diseases, and intestinal fermentation disorders. The acid tolerant microorganism Lactobacillus sakei Probio-65(KCTC 10755BP) is provided, wherein Lactobacillus sakei Probio-65(KCTC 10755BP) is isolated from Kimchi. A composition for inhibiting growth of pathogenic microorganisms comprises Lactobacillus sakei Probio-65(KCTC 10755BP) or its cultured medium. A composition for inhibiting growth of pathogenic microorganisms comprises Lactobacillus sakei Probio-65(KCTC 10755BP) or its cultured medium. An anti-atopic composition comprises Lactobacillus sakei Probio-65(KCTC 10755BP) or its cultured medium. A composition for inhibiting intestinal fermentation disorders comprises Lactobacillus sakei Probio-65(KCTC 10755BP) or its cultured medium. An anti-allergic composition comprises Lactobacillus sakei Probio-65(KCTC 10755BP) or its cultured medium.
The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.
Papulo-pustules in the skin of patients suffering from various forms of acne, folliculitis and rosacea may be rapidly resolved by a spot therapy which involves topically applying to the exterior surface of the papulo-pustule (pimple) an aqueous solution containing hydrogen peroxide and preferably also at least one fruit acid and/or salicylic acid. A preferred fruit acid is glycolic acid. Both open and closed comedones are also effectively treated by spot therapy with the aqueous solution containing hydrogen peroxide, fruit acid and salicylic acid. The solution preferably contains 3 to 6 weight percent hydrogen peroxide, 2 to 4 weight percent glycolic acid and 2 to 4 weight percent salicylic acid, and is preferably applied 2 to 3 times daily. Treatments continue for 1 to 3 days when directed to papulo-pustules and 7 to 20 days when directed to comedones. The therapy also substantially reduces or avoids hyperpigmentation and scarring after resorption of the papulo-pustules. Application of the hydrogen peroxide solution to the earliest spot (lesion) prevents developement of larger papulo-pustules and reduces the possibility of scarring and hyperpigmentation.
This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
A method of treating a material, the method comprising contacting the material with a composition comprising a compound of formula (I): Wherein R is an optionally substituted hydrocarbyl group having at least five carbon atoms and R1 is hydrogen or a solubilising group is provided. The material may be a keratinous material such as hair. The R group may be phenyl or CH3(CH2)n wherein n is from 4 to 10. The composition may further comprise surfactants, an alpha-substituted aldehyde and/or a hydroxy aldehyde, a polycarboxylic acid derived chelating agent, an amine salt of a carboxylic acid and a cross-linking agent comprising two or more maleic acid derived reactive moieties with a linker have two or more amino groups. A hair care composition comprising a compound of formula (I) is also provided. The use of a compound of formula (I) to enhance at least one property of hair is outlined. A packaged hair colouring product comprising one or more compositions wherein the one or compositions together comprise at least one dye compound and/or one dye precursor compound a compound of formula (I) is provided.
Carefully consider the potential benefits and risks of NAPROSYN Suspension and other treatment options before deciding to use NAPROSYN Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. 

After observing the response to initial therapy with NAPROSYN Suspension, the dose and frequency should be adjusted to suit an individual patient’s needs.

Always use a calibrated measuring device when administering NAPROSYN suspension to ensure the dose is measured and administered accurately. A household teaspoon or tablespoon is not an adequate measuring device, especially when one-half of a teaspoonful is to be measured. Given the variability of the household spoon measure, it is strongly recommended that caregivers obtain and use a calibrated measuring device. Health care providers should recommend an appropriate measuring device that can measure and deliver the prescribed dose accurately, and instruct caregivers to use extreme caution in measuring the dosage.

Naproxen-containing products such as NAPROSYN suspension, and other naproxen products should not be used concomitantly since they all circulate in the plasma as the naproxen anion.